Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Clasificación en acciones #41418
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Precio por acción
$0.0001
Última sincronización: 2025-06-11
Capitalización bursátil
$21.52K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CA
Comercio Diagnocure, Inc. (DGCRF)

Categoría

Ganancias de Diagnocure, Inc. (DGCRF)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Diagnocure, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Diagnocure, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras